Key Takeaways
Hong Kong announced a plan to establish itself as an international medical innovation hub, leveraging regulatory reforms and over HK$20 billion (US$2.6 billion) in new funding to attract global biotech talent and capital.
“The goal is to develop Hong Kong into a health and medical innovation hub,” Chief Executive John Lee said at the Asia Summit on Global Health on May 11, outlining a strategy that aligns with China’s 15th Five-Year Plan and aims to accelerate the delivery of new drugs and medical technologies.
Central to the plan is a new “1+” mechanism for drug registration, which allows new therapies to gain approval in Hong Kong with data from just one recognized reference authority, down from the traditional two. The city will also establish the Hong Kong Centre for Medical Products Regulation (CMPR) by the end of the year, which will introduce a “primary evaluation” pathway for new drugs, with the goal of creating a fully independent drug evaluation framework by 2030.
The government is backing the strategy with two funds of HK$10 billion each: the Research, Academic & Industry Sectors One-plus Scheme to support university research commercialization, and the New Industrialisation Acceleration Scheme to help companies establish smart production facilities in Hong Kong.
The policy changes are already being welcomed by the pharmaceutical industry. BeOne Medicines (Nasdaq: ONC), which was recently named “Outstanding Global Oncology Company of the Year” at the HKCT Business Awards 2026, signaled its intent to expand its footprint in the city.
“We will continue to advance our plans in Hong Kong by leveraging opportunities enabled by the ‘1+’ policy and the planned establishment of the Hong Kong Centre for Medical Products Regulation,” Richard Cheng, Associate Commercial Director at BeOne, said in a statement. The company plans to use its global supply network to bring more medicines to Hong Kong and the Greater Bay Area.
A key pillar of the strategy is the integration with the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). The government-owned Greater Bay Area International Clinical Trial Institute, located in the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone, will operate under an integrated model with its Shenzhen counterpart.
This "one institute, one centre" model aims to streamline cross-boundary clinical trials by drawing on the GBA's combined population of over 87 million, creating a one-stop agency for medical R&D institutions worldwide.
The combination of faster regulatory approvals, substantial government funding, and access to a vast patient population for clinical trials positions Hong Kong to become a formidable competitor for biotech investment in Asia. The success of these initiatives will depend on the swift implementation of the new regulatory bodies and the continued flow of capital into the city's burgeoning life sciences sector.
This article is for informational purposes only and does not constitute investment advice.
